Development of selective amyloid-responsive fluorescent probes

选择性淀粉样蛋白响应荧光探针的开发

基本信息

批准号：
10467922
负责人：
Jerry Yang
金额：
$ 193.43万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10467922
关键词：
Address Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer&apos s disease patient Amyloid Amyloid beta-Protein Amyloid deposition Amyloidosis Antineutrophil Cytoplasmic Antibodies Attention Binding Biological Products Brain Cadaver Cerebrospinal Fluid Characteristics Charge Chemicals Clinical Clinical Trials Complex Data Dementia Deposition Detection Development Diagnosis Diagnostic Disease Docking Early Diagnosis Event Exhibits Eye Family Fluorescence Fluorescent Probes Frontotemporal Dementia Goals Human Image Measurement Methods Monitor Nerve Degeneration Neurodegenerative Disorders Optical Methods Optics Parkinson Disease Patients Phase III Clinical Trials Positron-Emission Tomography Property Proteins Reporting Research Retina Sampling Sensitivity and Specificity Shapes Symptoms Systemic disease Tauopathies Techniques Technology Testing Tissues Translating Work alpha synuclein amyloid formation base brain tissue cost design diagnostic tool dipole moment disease diagnosis disorder risk fluorescence imaging fluorophore in silico interest lens misfolded protein mouse model nanopore neuropathology novel pre-clinical protein aggregation protein distribution radioligand ratiometric retinal imaging sensor technology single molecule synucleinopathy tau Proteins tool

项目摘要

Project Summary Amyloid accumulation in the brain is a universal feature of Alzheimer’s disease (AD) and many other related dementias and precedes clinical symptoms by several years. Methods for antemortem detection of amyloid species may, therefore, aid in diagnosing and monitoring neurodegeneration, providing critical information that can be used to devise a proper plan for patient management. While a number of clinical tools for detecting amyloid in the brain or cerebral spinal fluid have been developed to help diagnose AD, methods to differentiate AD from non-AD neuropathology in living patients are limited. We have recently developed two new families of fluorescent probes that can selectively detect aggregated forms of tau or alpha-synuclein, which could address an unmet need by extending the available toolbox for aiding in detection of amyloid or amyloid-like aggregates associated with non-AD diseases such as Frontotemporal Dementia (FTD), Parkinson’s disease (PD), and other tauopathies and synucleinopathies. The proposed research seeks to uncover new and reliable design principles for developing such selective amyloid-responsive probes and will seek to evaluate their utility for detection of amyloid species in emerging platforms for antemortem diagnostics. The Specific Aims of this proposal are to: 1) Develop fluorescent probes that exhibit selective enhancement of fluorescence upon binding to aggregated alpha-synuclein or tau versus ABeta in solution and in tissue; 2) Develop a method to characterize the distribution of aggregates of amyloidogenic proteins in biofluids; and 3) Evaluate whether selective amyloid-responsive fluorescent probes can be used to image specific amyloid deposits in the retina.

项目概要大脑中淀粉样蛋白的积累是阿尔茨海默病 (AD) 和许多其他相关疾病的普遍特征痴呆症并早于临床症状几年的淀粉样蛋白检测方法。因此，物种可能有助于诊断和监测神经退行性变，提供关键信息可用于制定适当的患者管理计划，同时使用许多临床工具进行检测。大脑或脑脊液中的淀粉样蛋白已被开发用于帮助诊断 AD、区分方法来自非 AD 神经病理学的活体患者的 AD 是有限的，我们最近开发了两个新的家族。荧光探针可以选择性地检测 tau 或 α-突触核蛋白的聚集形式，这可以解决通过扩展可用的工具箱来帮助检测淀粉样蛋白或淀粉样蛋白样聚集体来满足未满足的需求与非 AD 疾病相关，例如额颞叶痴呆 (FTD)、帕金森病 (PD) 和其他疾病拟议的研究旨在揭示新的、可靠的设计原理。开发这种选择性淀粉样蛋白反应探针，并将寻求评估它们在检测淀粉样蛋白中的效用新兴平台中的淀粉样蛋白种类用于生前诊断该提案的具体目标是： 1) 开发荧光探针，在与聚集体结合后表现出选择性增强的荧光 α-突触核蛋白或 tau 与溶液和组织中的 Aβ 2) 开发一种表征 α-突触核蛋白或 tau 蛋白分布的方法；生物体液中淀粉样蛋白的聚集体；3) 评估是否具有选择性淀粉样蛋白反应性荧光探针可用于对视网膜中特定的淀粉样沉积物进行成像。